United-Guardian's 2025 Results Confirm Sharp Sales and Profit Declines, Amplifying DeepValue's Risk Warnings

What happened

United-Guardian reported full-year 2025 financial results with a 13% decrease in net sales and a 35% drop in net income, continuing the downward trend observed in earlier quarters. This decline is primarily driven by a sharp fall in high-margin Lubrajel sales, which had already decreased by 56-65% in 9M25 due to reduced orders from key distributor Ashland into China, as highlighted in the DeepValue report. The company's heavy reliance on a few customers and exposure to volatile markets has exacerbated the revenue slump, with no immediate signs of recovery in its core cosmetic ingredient segment. Despite maintaining profitability and a net-cash balance sheet, UG's earnings per share fell to $0.46 from $0.71, reflecting compressed margins amid ongoing operational and regulatory pressures. These results underscore the critical need for UG to stabilize its cosmetic business and accelerate diversification efforts, such as Natrajel commercialization, to mitigate concentration risks.

Implication

The confirmed decline in 2025 sales and income validates the DeepValue report's concerns about Lubrajel's volatility and extreme customer concentration, suggesting the market has rightly priced in these challenges. UG's valuation, which was already estimated at a ~33% discount to intrinsic value, may face further pressure if cosmetic sales fail to stabilize in 2026, eroding the margin of safety. The persistent drop in earnings highlights the urgency for management to execute on diversification through Natrajel and geographic expansion, but delays and competitive threats cap near-term upside. With Medicare rebate pressures looming and ongoing China exposure, the investment case remains capped, suitable only for risk-tolerant, income-oriented microcap investors. Consequently, monitoring quarterly sales trends and new customer wins is essential, as any failure to recover volumes could trigger a more negative thesis.

Thesis delta

The news does not fundamentally alter the DeepValue thesis but solidifies the downside risks and urgency around the 'watch items'. UG's inability to arrest the sales decline in 2025 suggests that the stabilization of cosmetic ingredient volumes is more critical than anticipated, potentially delaying any upgrade to a stronger buy. This reinforces the need for clear evidence of recovery or successful diversification before the thesis can shift positively.